St. Louis firm, backed by $200M in funding, gets regulatory nods to 'expedite' review of cancer drug

St. Louis Business Journal

May 27, 2024

St. Louis biotechnology startup Wugen, which has raised more than $200 million in venture funding as it develops cancer-fighting drugs, has received two key regulatory designations…